Home
ACE Reports
All Specialties All Specialties All Specialties Arthroplasty Arthroplasty Arthroplasty Evidence Based Medicine Evidence Based Medicine Evidence Based Medicine Foot & Ankle Foot & Ankle Foot & Ankle General Orthopaedics General Orthopaedics General Orthopaedics Hand & Wrist Hand & Wrist Hand & Wrist Metabolic Disorders Metabolic Disorders Metabolic Disorders Osteoarthritis Osteoarthritis Osteoarthritis Pediatric Orthopaedics Pediatric Orthopaedics Pediatric Orthopaedics Peri-Operative Peri-Operative Peri-Operative Physical Therapy & Rehab Physical Therapy & Rehab Physio & Rehab Shoulder & Elbow Shoulder & Elbow Shoulder & Elbow Spine Spine Spine Sports Medicine Sports Medicine Sports Medicine Trauma Trauma Trauma Tumour Tumour Tumour Author Interviews Author Interviews Author Interview Conference Report Conference Report Conference Reports
Original Content
News
Multimedia
About
Search
Home
ACE Reports
Arthroplasty Evidence Based Medicine Foot & Ankle General Orthopaedics Hand & Wrist Metabolic Disorders Osteoarthritis Pediatric Orthopaedics Peri-Operative Physical Therapy & Rehab Shoulder & Elbow Spine Sports Medicine Trauma Tumour Author Interviews Conference Report
Original Content
News
Multimedia
About
Search
Previous Ace Report Better functional outcomes with eccentric exercise training following ACL reconstruction Next Ace Report Better functional outcomes with eccentric exercise training following ACL reconstruction
Ace Report Cover
Arthroplasty
Dabigatran is an inferior thromboembolism prophylactic treatment compared to enoxaparin
Reprints
Cite This
Reprints
Cite This
AceReport Image
Arthroplasty
Dabigatran is an inferior thromboembolism prophylactic treatment compared to enoxaparin
J Arthroplasty. 2009 Jan;24(1):1-9. Epub 2008 Apr 14
Contributing Authors

RE-MOBILIZE Writing Committee JS Ginsberg BL Davidson PC Comp CW Francis RJ Friedman MH Huo JR Lieberman JE Muntz GE Raskob ML Clements S Hantel JM Schnee JA Caprini

1896 patients scheduled to undergo total knee arthroplasty were randomized to one of three thromboembolism prophylaxis treatments to determine the best prophylaxis option. Patients either received an oral 220 mg dose of dabigatran once daily, an oral 150 mg dose of dabigatran once daily, or a 30 mg injection of enoxaparin twice daily. The results from this study indicated that both treatments of dabigatran were inferior in comparison to the standard enoxaparin in prevention of venous thromboembolism (VTE).

Unlock the full article

Get unlimited access to OrthoEvidence with a free trial
Start Trial

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or continue reading this full article
Register Now
AskOE
Search
Close Search Window
Welcome Back!
Forgot Password?
Create an Account

Account will be affiliated with

OR
Forgot Password?
OR
Check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see the email, please check your spam or junk folder.

For further assistance, contact our support team.

Cite this Ace Report

OrthoEvidence. Dabigatran is an inferior thromboembolism prophylactic treatment compared to enoxaparin . ACE Report. 2013;3(5):50. Available from: https://myorthoevidence.com/AceReport/Report/

Copy Citation
Share this Ace Report